SEC Form SC 13D/A filed by MetLife Inc. (Amendment)

$MET
Life Insurance
Finance
Get the next $MET alert in real time by email
SC 13D/A 1 d559074dsc13da.htm SC 13D/A SC 13D/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

AMENDMENT NO. 95 TO

SCHEDULE 13D

Under the Securities Exchange Act of 1934

 

 

MetLife, Inc.

(Name of Issuer)

Common Stock, par value $.01 per share

(Title of Class of Securities)

59156R108

(CUSIP Number)

Monica M. Curtis

Executive Vice President and Chief Legal Officer

MetLife, Inc.

200 Park Avenue

New York, NY 10166-0188

(212) 578-9500

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

November 2, 2023

(Date of Event which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

 

 

 

   

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


SCHEDULE 13D

 

CUSIP No. 59156R108   Page 2 of 9 Pages 

 

 (1)   

Names of Reporting Persons         Board of Directors of MetLife, Inc., as an entity

 

I.R.S. Identification

Nos. of Above Persons             Not applicable

 (2)  

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 (3)  

SEC Use Only

 

 (4)  

Source of Funds

 

 Not Applicable. See Item 4.

 (5)  

Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

 

 ☐

 (6)  

Citizenship or Place of Organization

 

 U.S.A.

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

 

    (7)    

Sole Voting Power

 

 0

    (8)   

Shared Voting Power

 

 118,254,445*

    (9)   

Sole Dispositive Power

 

 0

   (10)   

Shared Dispositive Power

 

 0

(11)  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

 118,254,445*

(12)  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

 ☐

(13)  

Percent of Class Represented by Amount in Row 11

 

 16.0%

(14)  

Type of Reporting Person

 

 IC

 

*

Unless otherwise indicated, all information relating to beneficial ownership of the Shares by the Reporting Persons is as of October 30, 2023.


SCHEDULE 13D

 

CUSIP No. 59156R108   Page 3 of 9 Pages

Items 4 and 5 are amended and restated as set forth below:

ITEM 4. PURPOSE OF TRANSACTION.

The Board of Directors (the “Board”) is reporting beneficial ownership of 118,254,445 shares of Common Stock (the “Shares”) held by the MetLife Policyholder Trust (the “Trust”) under the Plan of Reorganization, dated September 28, 1999, as amended (the “Plan”), of Metropolitan Life Insurance Company (“MetLife”).

On April 7, 2000, 494,466,664 Shares were issued to the Trust pursuant to Section 5.2(d) of the Plan, a copy of which is attached as an exhibit to this statement. No consideration has been separately provided therefor by any member of the Board, except for Shares allocated to such member pursuant to the Plan. Since April 7, 2000, transactions by Beneficiaries (i) under the Purchase and Sale Program provided for by the Trust Agreement (as defined below), (ii) pursuant to the Issuer’s split-off of Reinsurance Group of America, Incorporated, in September 2008, and (iii) to withdraw Shares from the Trust, as well as escheatment of unclaimed Shares, have resulted in a decrease in the number of Shares held by the Trust from 494,466,664
to 118,254,445 (as adjusted to reflect refinements in the calculation of the number of Shares issued to the Trust under the Plan).

Under the Plan and the MetLife Policyholder Trust Agreement, dated as of November 3, 1999 (as amended, the “Trust Agreement”), by and among MetLife, the Issuer, Wilmington Trust Company (the “Trustee”) and ChaseMellon Shareholder Services, L.L.C., as custodian (now known as Computershare Inc., the “Custodian”), a copy of which is attached as an exhibit to this statement, certain eligible policyholders of MetLife (“Trust Eligible Policyholders”) have been allocated a number of interests in the Trust (“Trust Interests”) equal to the number of shares of Common Stock allocated to the Trust Eligible Policyholders in accordance with the Plan. The assets of the Trust principally are the Shares issued to the Trust for the benefit of the Trust Eligible Policyholders and permitted transferees (collectively, the “Beneficiaries”). The Shares are held in the name of the Trustee, on behalf of the Trust, which has legal title over the Shares. The Beneficiaries do not have legal title to any part of the assets of the Trust. The Trust Interests represent undivided fractional interests in the Shares and other assets of the Trust beneficially owned by a Trust Beneficiary through the Custodian.

The Trust Agreement provides the Trustee with directions as to the manner in which to vote, assent or consent the Shares at all times during the term of the Trust. On all matters brought for a vote before the stockholders of the Issuer, with the exception of a Beneficiary Consent Matter (as defined below), the Trustee will vote in accordance with the recommendation given by the Board of the Issuer to its stockholders or, if no such recommendation is given, as directed by the Board. On all Beneficiary Consent Matters, the Trustee will vote all of the Shares in favor of, in opposition to or abstain from the matter in the same ratio as the Trust Interests of the Beneficiaries that returned voting instructions to the Trustee indicated preferences for voting in favor of, in opposition to or abstaining from such matter. The Trust Agreement also contains provisions allowing Beneficiaries to instruct the Custodian to withdraw their allocated Trust Shares to participate in any tender or exchange offer for the Common Stock and to make any cash or share election, or perfect any dissenter’s rights, in connection with a merger of the Issuer.


SCHEDULE 13D

 

CUSIP No. 59156R108   Page 4 of 9 Pages

A “Beneficiary Consent Matter” is:

 

  (i)

a contested election of directors or, subject to certain conditions, the removal of a director,

 

  (ii)

a merger or consolidation, a sale, lease or exchange of all or substantially all of the assets or a recapitalization or dissolution of the Issuer, if it requires a vote of stockholders under applicable Delaware law,

 

  (iii)

any transaction that would result in an exchange or conversion of the Shares for cash, securities or other property,

 

  (iv)

issuances of Common Stock prior to the first anniversary of the effective date of the Plan (the “Effective Date”) at a price materially below the prevailing market price, if a vote is required to approve the issuance under Delaware law, other than issuances in an underwritten public offering or pursuant to an employee benefit plan,

 

  (v)

before the first anniversary of the Effective Date, any matter that requires approval by a vote of more than a majority of the outstanding stock of the Issuer entitled to vote thereon under Delaware law or the certificate of incorporation or the by-laws of the Issuer, and any amendment to the certificate of incorporation or by-laws of the Issuer that is submitted to a vote of stockholders for approval, and

 

  (vi)

proposals submitted to stockholders requiring the Board to amend the Issuer’s stockholder rights plan, or redeem rights under that plan, other than a proposal with respect to which the Issuer has received advice of nationally-recognized legal counsel to the effect that the proposal is not a proper subject for stockholder action under Delaware law. The Issuer does not currently have a stockholder rights plan.

The Trust Agreement contains provisions enabling the Beneficiaries to withdraw the Shares allocated to them under the Plan and the Trust Agreement for resale or otherwise and to receive dividends on such Shares.


SCHEDULE 13D

 

CUSIP No. 59156R108   Page 5 of 9 Pages

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

 

(a)

As an entity, the Board of the Issuer beneficially owns 118,254,445 shares, or 16.0% of the Issuer’s outstanding Common Stock. The Board of the Issuer is deemed to beneficially own the shares of Common Stock held by the Trust because the Board will direct the voting of these shares on certain matters submitted to a vote of stockholders. See Item 4.

 

(b)

As an entity, the Board of the Issuer has shared voting power with respect to 118,254,445 shares of Common Stock.

 

(c)

There were no transactions in the class of securities reported on that were effected by the Reporting Persons since July 31, 2023 other than transactions described in Item 4 which resulted in a decrease in the number of shares of Common Stock held by the Trust from 120,043,226 to 118,254,445.

 

(d)

The Beneficiaries of the Trust have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares allocated to them under the Plan and the Trust Agreement. See Item 4.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Exhibit 99.1 Joint Filing Agreement under Rule 13d-1(k)(1)


SCHEDULE 13D

 

CUSIP No. 59156R108   Page 6 of 9 Pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

Dated: November 2, 2023

 

*

Cheryl W. Grisé

    

*

Carlos M. Gutierrez

    

*

Carla A. Harris

    

*

Gerald L. Hassell

    

*

David L. Herzog

    

*

R. Glenn Hubbard

    

*

Jeh C. Johnson

    

*

Edward J. Kelly, III

    

*

William E. Kennard

    

*

Michel A. Khalaf

    

*

Catherine R. Kinney

    

*

Diana L. McKenzie

    

*

Denise M. Morrison

    

*

Mark A. Weinberger

    


SCHEDULE 13D

 

CUSIP No. 59156R108   Page 7 of 9 Pages

 

       * By    /s/ John A. Hall
    John A. Hall
    Attorney-in-fact
Get the next $MET alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MET

DatePrice TargetRatingAnalyst
1/23/2025$97.00Market Perform
BMO Capital Markets
10/9/2024$97.00Buy
TD Cowen
9/5/2024$91.00Overweight
Barclays
1/8/2024$80.00Neutral → Buy
Goldman
11/17/2023$71.00Overweight
Barclays
10/5/2023$71.00Hold
Deutsche Bank
9/14/2023$58.00 → $72.00Hold → Buy
Jefferies
1/9/2023$80.00 → $78.00Buy → Neutral
Goldman
More analyst ratings

$MET
Press Releases

Fastest customizable press release news feed in the world

See more
  • MetLife Announced as 2025 CIO 100 Award Winner

    My Leave Navigator Supports Individuals Planning Time Away from Work Due to a Planned or Unexpected Life Event MetLife, Inc. (NYSE:MET) has been named as a 2025 CIO 100 Award Winner by Foundry CIO for My Leave Navigator. For almost 30 years, the CIO 100 Awards have recognized innovative organizations that exemplify the highest level of strategic and operational excellence in IT. "Receiving the CIO 100 Award for My Leave Navigator is a testament to our relentless pursuit of innovation that delivers real value for our customers," said Bill Pappas, MetLife's Head of Global Technology and Operations. My Leave Navigator is a part of MetLife's MyBenefits digital experience that support employe

    $MET
    Life Insurance
    Finance
  • AM Best Assigns Issue Credit Rating to MetLife, Inc.'s New Subordinated Notes

    AM Best has assigned a Long-Term Issue Credit Rating of "bbb+" (Good) to the newly issued $1 billion, 6.35% subordinated notes, due March 15, 2055, issued by MetLife, Inc. (MetLife) (headquartered in New York, NY) (NYSE:MET). The outlook assigned to this Credit Rating (rating) is stable. All other ratings of MetLife and its subsidiaries remain unchanged. MetLife's proforma adjusted financial leverage and the historical interest coverage are in line with its current ratings, and its holding company liquidity is strong. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, inc

    $MET
    Life Insurance
    Finance
  • MetLife Xcelerator Hits 4.5 Million Active Consumers and Surpasses $200M in Premiums

    MetLife Xcelerator evolves and transforms into a business unit to transform embedded insurance in the region. Driving insurance inclusion through disruptive technology, strategic partnerships, and a fully digital access model as part of MetLife's New Frontier strategy. MetLife, a global leader in insurance solutions, announces the creation of a new regional business unit in Latin America by the name of MetLife Xcelerator, marking a significant milestone in the evolution of the MetLife Xcelerator platform and execution of the company's New Frontier strategy. Designed to lead the transformation of embedded insurance and democratize access to financial protection, the MetLife Xcelerator p

    $MET
    Life Insurance
    Finance

$MET
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MET
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MET
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MET
SEC Filings

See more

$MET
Leadership Updates

Live Leadership Updates

See more
  • MetLife Investment Management Agrees to Acquire Traditional Fixed Income and Equity Portfolio Management Teams Managing $6 Billion From Mesirow

    Acquisition includes high yield, strategic fixed income and small-cap equity teams MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE:MET), today announced that it has reached a definitive agreement to acquire three investment teams and assets managed by Mesirow, an independent, employee-owned financial services firm. MIM is acquiring the high yield and bank loan, strategic fixed income and small-cap equity teams and certain related investment products. Under the terms of the transaction, about $6 billion of assets managed by the acquired teams will transfer to MIM, subject to customary approvals and consents. The acquisition is consi

    $MET
    Life Insurance
    Finance
  • MetLife Investment Management Names Kerry O'Brien Global Head of Insurance Asset Management and Liability Solutions

    MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE:MET), today announced that it has appointed Kerry O'Brien as global head of Insurance Asset Management and Liability Solutions. She will be responsible for the execution of investment strategies for the MetLife general account, helping drive growth in MIM's third-party insurance client channel as well as working with teams to drive liability solutions across other client segments. O'Brien will lead a team with an insurance investing heritage of nearly 150 years and an active role in managing MetLife's $414.1 billion general account as well as assets for third-party insurance clients. Sh

    $MET
    Life Insurance
    Finance
  • MetLife Worldwide Benefits and GeoBlue® to Offer Joint Solution

    Combining the medical and ancillary strengths of two leading global carriers into a single solution -- Globaline™ MetLife and GeoBlue, the international solution for the Blue Cross® Blue Shield® companies, announced today they will offer a full suite of expatriate benefit products in a best-in-class single solution, Globaline™. Globaline™ brings together health coverage and services from GeoBlue – including medical, dental, vision, prescription, wellness, international employee assistance program and political and natural disaster assistance – and life, accidental death & dismemberment and long term disability coverage from MetLife Worldwide Benefits, including value-added services, such

    $MET
    Life Insurance
    Finance

$MET
Financials

Live finance-specific insights

See more
  • MetLife Confirms First Quarter 2025 Series A Preferred Stock Dividend

    MetLife, Inc. (NYSE:MET) today announced that it has confirmed its previously announced declaration of the first quarter 2025 dividend of $0.35516415 per share on the company's floating rate non-cumulative preferred stock, Series A, with a liquidation preference of $25 per share (NYSE:MET). The New York Stock Exchange has not yet set an ex-dividend date for the Series A preferred stock. Following this confirmatory announcement, the New York Stock Exchange will set an ex-dividend date for the Series A preferred stock. The dividend will be payable March 17, 2025, to shareholders of record as of Feb. 28, 2025, due to the record date occurring on Sunday, March 2, 2025. About MetLife MetLife,

    $MET
    Life Insurance
    Finance
  • MetLife Announces First Quarter 2025 Preferred Stock Dividend Actions

    Declares Series D, E, F and G Preferred Stock Dividends Declares Series A Preferred Stock Dividend, Subject to Final Confirmation MetLife, Inc. (NYSE:MET) today announced that it has declared the following preferred stock dividends: Semi-annual dividend of $29.375 per share on the company's 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a liquidation preference of $1,000 per share. Quarterly dividend of $351.5625 per share on the company's 5.625% non-cumulative preferred stock, Series E, with a liquidation preference of $25,000 per share, represented by depositary shares each representing 1/1,000th interest in a share of the preferred stock, holders of wh

    $MET
    Life Insurance
    Finance
  • MetLife Announces Full Year and Fourth Quarter 2024 Results

    MetLife, Inc. (NYSE:MET) today announced its full year and fourth quarter 2024 results. Full Year Results Summary Net income of $4.2 billion, compared to net income of $1.4 billion for the full year 2023. Net income of $5.94 per share, up 228 percent from the prior year. Adjusted earnings of $5.8 billion, compared to adjusted earnings of $5.5 billion for the full year 2023. Adjusted earnings of $8.15 per share, up 12 percent from the prior year. Adjusted earnings, excluding total notable items, of $5.8 billion, compared to $5.6 billion for the full year 2023. On a per share basis, adjusted earnings, excluding total notable items, of $8.11, up 11 percent from $7.33 for the full ye

    $MET
    Life Insurance
    Finance

$MET
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more